Before-and-after photos
As demonstrated in these unretouched photos of results following 12 weeks of treatment with Acanya® Gel:
19-year-old male patient |
20-year-old female patient |
|
|
| Before treatment |
After treatment |
|
| Before treatment |
After treatment |
|
15-year-old male patient |
17-year-old female patient |
|
|
| Before treatment |
After treatment |
|
| Before treatment |
After treatment |
|
These unretouched photos represent actual clinical trial experience. As with all treatments, results may vary from person to person.
Proven effective in moderate to severe acne
As shown in 2 double-blind, randomized, controlled studies of 2813 patients with moderate to severe acne:
- Data reflect the median percentage reduction in inflammatory lesions and noninflammatory lesions from baseline to week 12 (intent-to-treat population, last observation carried forward [LOCF])1, 2
- 55% mean reduction in inflammatory lesions at week 12 (vehicle 29%); p<0.0011, 3
- 43% mean reduction in noninflammatory lesions at week 12 (vehicle 24%); p≤0.0011, 3
64% median reduction in inflammatory lesions at 12 weeks
49% median reduction in noninflammatory lesions at 12 weeks
References: 1. Pivotal studies data on file, CORIA Laboratories. 2. Gold M. A new, once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderate-to-severe acne. J Clin Aesthet Derm. 2009;5:44-48. 3. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59:792-800.
Indication and Important Safety Information: Acanya Gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. Do not prescribe if the patient has shown hypersensitivity to clindamycin, benzoyl peroxide, or to lincomycin. Acanya Gel is contraindicated in patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. Discontinuation is recommended if significant diarrhea, bloody diarrhea, severe abdominal cramping, or colitis (including pseudomembranous colitis) develops. Clindamycin taken orally or through IV may result in severe colitis, which may result in death. Anaphylaxis, as well as other allergic reactions leading to hospitalizations, has been reported in postmarketing use of products containing clindamycin/benzoyl peroxide. If a patient develops symptoms of an allergic reaction such as swelling and shortness of breath, they should be instructed to discontinue use and contact a physician immediately. Patients should be advised to avoid contact with the eyes or mucous membranes and to minimize sun exposure following the application of Acanya Gel. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application site irritation (0.1%).
